Prevalence and predictors of discharge polypharmacy in geriatric patients discharged from an Indonesian teaching hospital: a retrospective observational study
Main Article Content
Keywords
discharge polypharmacy, prevalence, elderly, chronic conditions, Indonesia
Abstract
Objective: The study aimed to investigate the prevalence and risk factors for discharge polypharmacy in geriatric patients in Indonesia. Methods: The retrospective cohort study used the medical record profiles of geriatric patients aged ≥ 60 years admitted to the inpatient ward between July 2018 and October 2019. Using three logistic regression models, we assessed the association of the patient’s demographic, clinical characteristics, and disease condition with discharge polypharmacy. The use of five or more medications was defined as discharge polypharmacy. Results: A total of 1533 patients were included in the study. Most patients (78.21%) aged between 60 and 74 years. The male-to-female patient ratio was almost the same (50.16% versus 49.83%). Of the patients (52.51%) were discharged with polypharmacy. According to regression model I, patients who had a chronic condition, comorbidity, stayed in the hospital for ≥ seven days, had a Charlson comorbidity index score (3-4), and received excessive polypharmacy (≥ 10 drugs) during admission had significantly more risk (p< 0.05) to receive polypharmacy at discharge. The results of model II investigated myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, diabetes with complications, renal disease, and high blood pressure as significant (p<0.05) predictors of discharge polypharmacy. The combined model III evaluated that comorbidity, length of hospital stay (7 or more days), excessive polypharmacy use in the hospital, myocardial infarction, and congestive heart failure were significantly (P < 0.05) associated with discharge polypharmacy. Conclusions: Polypharmacy is common in Indonesia and is linked to certain chronic conditions and other clinical factors. A particular plan that includes a pharmacist and physician collaborative relationship and awareness of the health outcomes of polypharmacy could be critical.
References
2. world Health Organisation. Novel Coronavirus – China. https://www.who.int/csr/don/12-january-2020-novel-coronaviruschina/ en/: WHO; 2020 8/June. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
3. Centers for disease control and prevention. COVID-19. CDC; 2021 16-June. Available from: https://www.cdc.gov/ coronavirus/2019-ncov/symptoms-testing/symptoms.html.
4. World Health Organisation. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-oncovid- 19---11-march-2020: WHO; 2020 8/June. Available from: https://www.who.int/director-general/speeches/detail/whodirector- general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
5. European Medicines Agency. Availability of medicines during COVID-19 pandemic European Medicines Agency; 2021 11-April. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-diseasecovid- 19/availability-medicines-during-covid-19-pandemic.
6. Haque M, Kumar S, Charan J, et al. Utilisation, availability and price changes of medicines and protection equipment for COVID-19 among selected regions in India: Findings and implications. Frontiers in pharmacology. 2021;11:582154.. https:// doi.org/10.3389/fphar.2020.582154
7. Reyes MV. STUDENT ESSAY The Disproportional Impact of COVID-19 on African Americans. http://www.ncbi.nlm.nih.gov/pmc/ articles/pmc7762908/
8. WOrld Health Organisation. COVID-19 dynamic infographic dashboard Iraq 2020-2022. WHO; 2022 7-June. Available from: https://app.powerbi.com/view?r=eyJrIjoiNjljMDhiYmItZTlhMS00MDlhLTg3MjItMDNmM2FhNzE5NmM4IiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9
9. Weekly epidemiological update on COVID-19 - 1 June 2021, (42, 2021).
10. Organization WH. WHO medicines strategy 2004-2007: countries at the core. 2004. World Health Organization.
11. Treasury HMs, Revenue I. Increasing access to essential medicines in the developing world: UK Government policy and plans.
12. Organization WH. The world medicines situation. 2004. World Health Organization.
13. McIntyre D, Thiede M, Dahlgren G, et al. What are the economic consequences for households of illness and of paying for health care in low-and middle-income country contexts? Social science & medicine. 2006;62(4):858-865. https://doi.org/10.1016/j. socscimed.2005.07.001
14. Bale H. Consumption and trade in off-patented medicines. WHO Commission for Macroeconomics and Health Working Paper, February. 2001.
15. Organization WH. WHO guideline on country pharmaceutical pricing policies. World Health Organization; 2015. ISBN: 9241549033.
16. Wagner JL, McCarthy E. International differences in drug prices. Annu Rev Public Health. 2004;25:475-495. https://doi. org/10.1146/annurev.publhealth.25.101802.123042
17. Kasapçopur Ö. A Big Problem and debate in COVID-19 pandemics: equitable and effective access of the COVID-19 vaccines and waiver of intellectual property. Turkish Archives of Pediatrics. 2021;56(4):283. https://doi.org/10.5152/ turkarchpediatr.2021.180621
18. Myhr K. Comparing prices of essential drugs between four East African countries and with international prices. Amsterdam: Health Action International. 2000;22:158-165.
19. Bala K, Sagoo K. Patents and prices. HAI news. 2000;112:1-11.
20. Gencarelli D. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? 2002;1(775):1- 19. http://www.ncbi.nlm.nih.gov/books/nbk561162/
21. Srivastava D, McGuire A. Analysis of prices paid by low-income countries-how price sensitive is government demand for medicines? BMC Public Health. 2014;14(1):1-12. https://doi.org/10.1186/1471-2458-14-767
22. Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The lancet. 2009;373(9659):240-249. https://doi.org/10.1016/s0140-6736(08)61762-6
23. Saeed A, Saeed H, Saleem Z, et al. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology. PloS one. 2019;14(4):e0216122. https://doi.org/10.1371/ journal.pone.0216122
24. The World Bank. GDP per capita (current US$). The World Bank; 2022 14-May. Available from: https://data.worldbank.org/ indicator/NY.GDP.PCAP.CD.
25. International Organization for Standardization. Country Codes Collection. 2023 11-June. Available from: https://www.iso.org/ obp/ui/#search/code/.
26. Haque M, Islam S, Iqbal S, et al. Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. Bangladesh Journal of Medical Science. 2020:36-S 50.
27. Aljadeed R, AlRuthia Y, Balkhi B, et al. The impact of COVID-19 on essential medicines and personal protective equipment availability and prices in Saudi Arabia. Healthcare; 2021. Multidisciplinary Digital Publishing Institute. 2021;9(3):290. https:// doi.org/10.3390/healthcare9030290
28. Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the pharmaceutical sector. Daru. 2020;28(2):799- 805. https://doi.org/10.1007/s40199-020-00358-5
29. Cohen J, Neumann P, Ollendorf D. Valuing and pricing remdesivir: should drug makers get paid for helping us get back to work. Health Affairs Blog https://www healthaffairs https://doi.org/101377/hblog20200518. 2020;966027
30. Institute for Clinical and Economic Review. Alternative pricing models for remdesivir and other potential treatments for COVID-19. Institute for Clinical and Economic Review; 2020 5-June. Available from: https://icer.org/news-insights/pressreleases/ alternative_pricing_models_for_remdesivir/.
31. Akour A, Elayeh E, Tubeileh R, et al. Role of community pharmacists in medication management during COVID-19 lockdown. Pathogens and Global Health. 2021 2021/04/03;115(3):168-177. https://doi.org/10.1080/20477724.2021.1884806.
32. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention Global Initiative for Asthma; 2022 5-June. Available from: https://ginasthma.org/wp-content/uploads/2022/05/GINA-Main-Report-2022-FINAL-22-05-03-WMS.pdf
33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal. 2003;21(1):74-81. https://doi.org/10.1183/09031936.03.00031402
34. Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respiratory investigation. 2020;58(3):155-168. https://doi.org/10.1016/j.resinv.2019.12.005
35. Heinen N, Meister TL, Klöhn M, et al. Antiviral Effect of Budesonide against SARS-CoV-2. Viruses. 2021;13(7):1411. https://doi. org/10.3390/v13071411.
36. National Institutes for Health and Care Excelence. COVID-19 rapid guideline: critical care in adults. NICE; 2020 5-June. Available from: https://www.nice.org.uk/guidance/ng159.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Shah Faisal, Doctoral Program of Pharmaceutical Sciences Study Program, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Surakit Nathisuwan, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Junaidi Khotib, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Susi Ari Kristina, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Gesnita Nugraheni, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.